Movement Alert｜3SBio Rises 5.95% at Open, ASCO Clinical Data for SSGJ-707 Continues to Drive Momentum

Market Focus06-01

On June 1, 3SBio rose 5.95% at open, trading at HK$19.6/share with trading volume of HK$24.56 million. The rally was driven by continued positive sentiment surrounding the ASCO annual meeting, where the company's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two clinical studies selected for presentation, with one receiving rapid oral presentation status.

According to published abstracts, SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with median PFS of 12.4 months in a Phase II study. In combination with chemotherapy for first-line endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively. Additionally, the company recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately US$6.05 billion, including a US$1.25 billion upfront payment, further validating the asset's global commercial potential. The broader biotech sector also traded stronger, with AKESO up 9.23% and REMEGEN up 2.6%, providing sector-level tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118165998?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118165998","market":"hk","top_or_hot":-1,"title":"Movement Alert｜3SBio Rises 5.95% at Open, ASCO Clinical Data for SSGJ-707 Continues to Drive Momentum","media":"Market Focus","content":"<p><p>On June 1, 3SBio rose 5.95% at open, trading at HK$19.6/share with trading volume of HK$24.56 million. The rally was driven by continued positive sentiment surrounding the ASCO annual meeting, where the company's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two clinical studies selected for presentation, with one receiving rapid oral presentation status.</p><p>According to published abstracts, SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with median PFS of 12.4 months in a Phase II study. In combination with chemotherapy for first-line endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively. Additionally, the company recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately US$6.05 billion, including a US$1.25 billion upfront payment, further validating the asset's global commercial potential. The broader biotech sector also traded stronger, with AKESO up 9.23% and REMEGEN up 2.6%, providing sector-level tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜3SBio Rises 5.95% at Open, ASCO Clinical Data for SSGJ-707 Continues to Drive Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜3SBio Rises 5.95% at Open, ASCO Clinical Data for SSGJ-707 Continues to Drive Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 09:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, 3SBio rose 5.95% at open, trading at HK$19.6/share with trading volume of HK$24.56 million. The rally was driven by continued positive sentiment surrounding the ASCO annual meeting, where the company's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two clinical studies selected for presentation, with one receiving rapid oral presentation status.</p><p>According to published abstracts, SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with median PFS of 12.4 months in a Phase II study. In combination with chemotherapy for first-line endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively. Additionally, the company recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately US$6.05 billion, including a US$1.25 billion upfront payment, further validating the asset's global commercial potential. The broader biotech sector also traded stronger, with AKESO up 9.23% and REMEGEN up 2.6%, providing sector-level tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1118165998","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118165998","pubTimestamp":1780276921,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, 3SBio rose 5.95% at open, trading at HK$19.6/share with trading volume of HK$24.56 million. The rally was driven by continued positive sentiment surrounding the ASCO annual meeting, where...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"动静提示|三生制药开盘涨5.95%SSGJ-707 ASCO临床数据继续推动动能","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"On June 1, 3SBio rose 5.95% at open, trading at HK$19.6/share with trading volume of HK$24.56 million. The rally was driven by continued positive sentiment surrounding the ASCO annual meeting, where the company's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two clinical studies selected for presentation, with one receiving rapid oral presentation status.According to published abstracts, SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with median PFS of 12.4 months in a Phase II study. In combination with chemotherapy for first-line endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively. Additionally, the company recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately US$6.05 billion, including a US$1.25 billion upfront payment, further validating the asset's global commercial potential. The broader biotech sector also traded stronger, with AKESO up 9.23% and REMEGEN up 2.6%, providing sector-level tailwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118165998","isCrawlerRequest":true}